PREVALENCE OF EXTENDED-SPECTRUM BETA-LACTAMASE PRODUCING ENTEROBACTERIACEAE MEMBERS ISOLATED FROM CLINICALLY SUSPECTED PATIENTS

Moorthy Kannaiyan; Gedif Meseret Abebe; Chinnasamy Kanimozhi; Punitha Thambidurai; Saranya Ashokapuram Selvam; Raja Vinodhini; Mickymaray Suresh

doi:10.22159/ajpcr.2018.v11i5.19363

Authors

Moorthy Kannaiyan Department of Microbiology, Vivekanandha College of Arts and Sciences for Women (Autonomous), Elayampalayam, Tiruchengode, Namakkal - 637 205, Tamil Nadu, India.
Gedif Meseret Abebe Department of Microbiology, Wolaita Sodo University, Wolaita Zone, Ethiopia, Eastern Africa.
Chinnasamy Kanimozhi Department of Microbiology, Vivekanandha College of Arts and Sciences for Women (Autonomous), Elayampalayam, Tiruchengode, Namakkal - 637 205, Tamil Nadu, India.
Punitha Thambidurai Department of Microbiology, San International College of Arts and Science, Mavuthampathy Village, (Walayar), Coimbatore - 641 105, Tamil Nadu, India.
Saranya Ashokapuram Selvam Department of Microbiology, Vivekanandha College of Arts and Sciences for Women (Autonomous), Elayampalayam, Tiruchengode, Namakkal - 637 205, Tamil Nadu, India.
Raja Vinodhini Department of Microbiology, Shri Sakthikailaassh Womenâ€™s College, Salem - 636 003, Tamil Nadu, India.
Mickymaray Suresh Department of Biology, Central Bioscience Research Laboratories (CBRL) College of Science, Al- Zulfi, Majmaah University-Majmaah 11952, Kingdom of Saudi Arabia.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i5.19363

Keywords:

Extended-spectrum beta-lactamase, Enterobacteriaceae, Escherichia coli, Enterobacter aerogenes and Klebsiella pneumoniae

Abstract

Â Objective: Emergence of extended-spectrum beta-lactamases (ESBLs) production poses another clinical problem with Gram-negative bacterial infections. The present study was aimed to evaluate the ESBL producers among various clinical samples of clinically suspected patients.

Methods: A total of 1279 samples (urine [918], pus [207] and stool [154]) were collected and 465 isolates (Escherichia coli [320], Enterobacter aerogenes [119] and Klebsiella pneumoniae [26]) were isolated and screened for the presence of ESBL producers using combination disc method and double disc synergy test.

Results: Of the 465 culture positive isolates, 130 (E. coli 93 [29.06%], E. aerogenes 35 [29.41%] and K. pneumoniae 2 [7.69%]) were identified as ESBL producers. Among the three Enterobacteriaceae members, E. coli 93 (29.06%) was found to be predominant ESBL producer next in order E. aerogenes 35 (29.41%) and K. pneumoniae 2 (7.69%). Maximum number of ESBL producers were recovered from urine (n=111) followed by pus (n=14) and stool (n=5). All the ESBL-producing isolates were subjected to antibiotic sensitivity test using 10 different antibiotics. ESBL producers were chiefly resistance to ceftriaxone followed by ceftazidime and cefotaxime. Of 130 ESBL producers, 15 (E. coli (8), E. aerogenes (6) and K. pneumoniae (1)] strains were selected for genotypic identification. Among, only two strains of E. aerogenes were positive isolates for CTX-M type ESBL in polymerase chain reaction.

Conclusion: This study concluded that among Enterobacteriaceae members, E. coli was the predominant ESBL producers and urine was noted as the prime source for the ESBL positive isolates when compared to other source. Genotypic identification was the best method to differentiate ESBL types which were essential to provide proper treatment.

Downloads

Download data is not yet available.

References

Knudsen JD, Andersen SE, Bispebjerg Intervention Group. A multidisciplinary intervention to reduce infections of ESBL-and ampC-producing, gram-negative bacteria at a university hospital. PLoS One 2014;9:e86457.

Jacoby GA, Medeiros AA. More extended spectrum Î² lactamases. Antimicrob Agents Chemother 1991;35:1697-704.

Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev 2005;18:657-86.

Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11:315-17.

Bonnet R, De Champs C, Sirot D, Chanal C, Labia R, Sirot J, et al. Diversity of TEM mutants in Proteus mirabilis. Antimicrob Agents Chemother 1999;43:2671-7.

Choi SH, Lee JE, Park SJ, Kim MN, Choo EJ, Kwak YG, et al. Prevalence, microbiology, and clinical characteristics of extended-spectrum beta-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea. Eur J Clin Microbiol Infect Dis 2007;26:557-61.

Ivanova D, Markovska R, Hadjieva N, Schneider I, Mitov I, Bauernfeind A. Extended-spectrum Î²-lactamaseproducing Serratia marcescens outbreak in a Bulgarian hospital. J Hosp Infect 2008;70:60-5.

Nakamura T, Komatsu M, Yamasaki K, Fukuda S, Miyamoto Y, Higuchi T, et al. Epidemiology of Escherichia coli, Klebsiella species, and Proteus mirabilis strains producing extended-spectrum Î²-lactamases from clinical samples in the Kinki region of Japan. Am J Clin Pathol 2012;137:620-6.

Bradford PA. Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.

Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for Î²-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.

Giamarellou H. Multidrug resistance in gram-negative bacteria that produce extended-spectrum b-lactamases (ESBLs). Clin Microbiol Infect 2005;11 Suppl 4:1-16.

Jacoby GA. Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams. Infect Dis Clin North Am 1997;11:875-87.

Bonnet R. Growing group of extended-spectrum Î²-lactamases: The CTX-M enzymes. Antimicrob Agents Chemother 2004;48:1-14.

Tzouvelekis LS, Tzelepi E, Tassios PT, Legakis NJ. CTX-mtype b-lactamases; An emerging group of extended-spectrum enzymes. Int J Antimicrob Agents 2000;14:137-43.

Bonnet R, Sampaio JL, Chanal C, Sirot D, De Champs C, Viallard JL, et al. A novel class a extended-spectrum beta-lactamase (BES-1) in Serratia marcescens isolated in Brazil. Antimicrob Agents Chemother 2000;44:3061-8.

Jean SS, Hsueh PR, Lee WS, Chang HT, Chou MY, Chen IS, et al. Nationwide surveillance of antimicrobial resistance among Enterobacteriaceae in intensive care units in Taiwan. Eur J Clin Microbiol Infect Dis 2009;28:215-20.

Batchoun RG, Swedan SF, Shurman AM. Extended spectrum Î²-lactamases among gram-negative bacterial isolates from clinical specimens in three major hospitals in Northern Jordan. Int J Microbio 2009. Article ID: 513874, 9 pages.

Collee JG, Fraser AG, Marmion BP, Simmons A. Mackie and McCartney Practical Medical Microbiology. 14th ed. London: Churchill Livingstone; 1996. p. 417-23.

Bauer AW, Kirby MD, Sherris JC, Turck M. Antibiotic susceptibility testing by standardized single disc diffusion method. Am J Clin Pathol 1966;45:493-6.

Clinical and Laboratory Standards Institute (CLSI). Performance Standard for Antimicrobial Susceptibility Testing. 16th Informational Supplement. Wayne, PA: CLSI Document M100-S16; 2006.

Clinical and Laboratory standards Institute (CLSI). Performance standard for Antimicrobial Susceptibility Testing. Wayne, PA. USA: CLSI Approved Standards CLSI M-100-S20; 2010.

Balan K. Detection of extended spectrum beta lactamase among gram negative clinical isolates from a tertiary care hospital in south India. Ind J Med Sci 2013;1:28-30.

Ansubel M, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, et al. Current Protocols in Molecular Biology. Vol. 1. New York, USA: Wiley & Sons, Inc.; 1995.

Woodford N, Fagan EJ, Ellington MJ. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum (beta)-lactamases. J Antimicrob Chemother 2006;57:154-5.

Altschul SF, Madden TL, SchÃ¤ffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res 1997;25:3389-402.

Yusuf I, Haruna M, Yahaya H. Prevalence and antibiotic susceptibility of Ampc and ESBL producing clinical isolates at a tertiary health care center in Kano, Northwest Nigeria. Afr J Cln Exper Microbiol 2013;2:109-19.

Patel MH, Trivedi GR, Patel SM, Vegad MM. Antibiotic susceptibility pattern in urinary isolates of gram negative bacilli with special reference to ampC Î²-lactamase in a tertiary care hospital. Urol Ann 2010;2:7-11.

Podschun R, Ullmann U. Klebsiella spp. As nosocomial pathogens: Epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998;11:589-603.

Soltani R, Ehsanpoor M, Khorvash F, Shokri MM. Antimicrobial susceptibility pattern of extended-spectrum Î²-lactamase-producing bacteria causing nosocomial urinary tract infections in an Iranian referral teaching hospital. J Res Pharm Pract 2014;3:6-11.

Umadevi S, Kandhakumari G, Joseph NM, Kumar S, Easow JM, Stephen S, et al. Prevalence and antimicrobial susceptibility pattern of ESBL producing gram negative bacilli. J Clin Diagn Res 2011;5:236-9.

Nazneen S, Jayshree B, Ajit D, Jyoti B. Prevalence of extended spectrum beta lactamase (ESBL) producing gram negative bacilli from various clinical isolates. IOSR J Dent and Med Sci 2014;13:8-11.

Chaudhary M, Kumar S, Payasi A. Prevalence and antimicrobial sensitivity of extended-spectrum Î²-lactamase producing gram negative bacteria from clinical settings in India from 2010-2012. Int J Med and Med Sci 2013;46:46-9.

Menon T, Bindu D, Kumar CP, Nalini S, Thirunarayan MA. Comparison of double disc and three dimensional methods to screen for ESBL producers in a tertiary care hospital. Indian J Med Microbiol 2006;24:117-20.

Shobha KL, Ramachandra L, Rao G, Majumder S, Rao SP. Extended spectrum beta-lactamases (ESBL) in gram negative bacilli at a tertiary care hospital. J Diagn Clin Res 2009;3:1307-12.

Nevine S, Fam M, El-Damarawy M. CTX-M-15 extended-spectrum beta-lactamases detected from intensive care unit of an Egyptian medical research institute. Res J Med Med Sci 2008;3:84-91.

Ullah F, Malik SA, Ahmed J. Antimicrobial susceptibility pattern and ESBL prevalence in Klebsiella pneumonia from urinary tract infection in the Northâ€“West of Pakistan. Afr J Microbiol Res 2009;3:676-80.

Tankhiwale SS, Jalgaonkar SV, Ahamad S, Hassani U. Evaluation of extended spectrum beta lactamase in urinary isolates. Indian J Med Res 2004;120:553-6.

Yusuf I, Arzai AH, Umar A, Magaji N, Salisu N, Tukur A, et al. Prevalence of extended spectrum beta lactamases (ESBL) producing Escherichia coli and Klebsiella pneumoniae in tuberculosis patients in Kano, Nigeria. Bajopas 2011;4:1.

Raja MM, Ahmed JS. Evaluation of extended spectrum of beta lactamases producing Escherichia coli isolated from hospitalized patients M. Int J Adv Res 2013;19:309-15.

Jain A, Roy I, Gupta MK, Mala K, Agarwal SK. Prevalence of extended-spectrum beta-lactamase producing Gram-negative bacteria in septicaemic neonates in a tertiary care hospital. J Med Microb 2003;52:421-5.

Sharma M, Pathak S, Preeti S. Prevalence and antibiogram of extended spectrum Î²-lactamase (ESBL) producing gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp. J Clin Diag Res 2013;7:2173-7.

Hansotia JB, Agarwal V, Pathak AA, Saoji AM. Extended spectrum beta-lactamase mediated resistance to third generation cephalosporins in Klebsiella pneumoniae in Nagpur, central India. Indian J Med Res 1997;105:158-61.

Dechen CT, Shyamasree D, Luna A, Ranabir P, Takhellambam SK. Extended spectrum beta-lactamase detection in gram-negative bacilli of nosocomial origin. J Glob Infect Dis 2009;1:87-92.

Shanthi M, Sekar U. Extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcomes. J Assoc Physicians India 2010;58 Suppl:41-4.

Iraj A, Nilufar YN. Antibiogram of extended spectrum beta-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae isolated from hospital samples. Bangladesh J Med Microbiol 2010;4:32-6.

Saba R, Muhammad F, Shahida H. Prevalence and comparison of beta-lactamase producing Escherichia coli and Klebsiella spp. from clinical and environmental sources in Lahore, Pakistan. Af J Microbio Res 2012;6:465-70.

Kulkarni R, Vaishali D, Ghadge D, Bhore A. A study of extended spectrum beta lactamases (ESBL) producers in clinical isolates. Med J West India 2013;41:18-22.

Shah RK, Singh YI, Sanjana RK, Navin C, Dominic S. Study of extended spectrum beta-lactamases (ESBLs) producing Klebsiella species in various clinical specimens: A preliminary report. J Coll Med Sci Nepal 2010;6:19-23.

Graffunder EM, Preston KE, Evans AM, Venezia A. Risk factors associated with extended-spectrum Î²-lactamase-producing organisms at a tertiary care hospital. J Antimicro Chemother 2005;56:139-45.

Harada Y, Morinaga Y, Yamada K, Migiyama Y, Nagaoka K, Nakamura U, et al. Clinical and molecular epidemiology of extended-spectrum Î²-lactamase-producing Klebsiella pneumoniae and Escherichia coli in a Japanese tertiary hospital. J Med Microb Diagn 2013;2:2161-70.

Yu Y, Zhou W, Chen Y, Ding Y, Ma Y. Epidemiological and antibiotic resistant study on extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumonia in Zhejiang province. Chin Med J (Engl) 2002;115:1479-82.

Das A, Ray P, Garg R, Kaur B. Proceedings of the Silver Jubilee Conference. New Delhi: All India Institute of Medical Sciences; Extended Spectrum Beta-Lactamase Production in Gram Negative Bacterial Isolates from Cases of Septicemia; 2001.

Ali AM, Rafi S, Qureshi AH. Frequency of Extended Spectrum Beta Lactamase Producing Gram Negative Bacilli among Clinical Isolates at Clinical Laboratories of Army Medical College, Rawalpindi. Available from: http://www.ayubmed.edu.pk/JAMC/PAST/16-1/Aarif.htm.

Nurul MA, Loo HK, Subramaniam G, Wong EH, Selvi P, Ho S, et al. Faecal prevalence of extended-spectrum ÃŸ-lactamase (ESBL)-producing coliforms in a geriatric population and among haematology patients. Malaysian J Pathol 2005;27:75-81.

Mohanty S, Singhal R, Sood S, Dhawan B, Das BK, Kapil A, et al. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria. Indian J Med Res 2005;122:425-8.

Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum beta lactamase producing gram negative bacteria in a tertiary care hospital. Indian J Med Res 2002;115:153-7.

Basavaraj PJ, Basavaraj PV. The prevalence of ESBL among Enterobacteriaceae in a tertiary care hospital of north Karnataka, India. J Clin Diag Res 2011;5:470-5.

Sharma A, Grover PS. Application of WHONET for the surveillance of antimicrobial resistance. Indian J Med Microbiol 2004;22:115-8.

Rodrigues C, Joshi P, Jani SH, Alphonse M, Radhakrishnan R, Mehta A. Detection Of Î²-lactamases in nosocomial gram negative clinical isolates. Indian J Med Microbiol 2004;22:247-50.

Kumar MS, Lakshmi V, Rajagopalan R. Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. Isolated at a tertiary care institute. Indian J Med Microbiol 2006;24:208-11.

Coudron PE, Moland ES, Sanders CC. Occurrence and detection of extended-spectrum ÃŸ-lactamases in members of the family Enterobacteriaceae at a veterans medical center: Seek and you may find. J Clin Microbiol 1997;35:2593-7.

El-mahdy TS, Abdelaziz MO, El-domany RA. Prevalence and molecular characterization of extended spectrum Î²-lactamases in Klebsiella pneumoniae isolates from cancer patients and others. Int J Pharm Pharm Sci 2015;7:122-12.

Nathisuwan S, Burgess DS, Lewis JS 2nd. ESBLs: Epidemiology, detection and treatment. Pharmacotherapy 2001;28:920-8.

Gupta V, Singla N, Jagdish C. Detection of sells using third and fourth generation cephalosporins in double disc synergy test. Indian J Med Res 2007;126:486-7.

Khurana S, Taneja N, Sharma M. Extended spectrum Î²-lactamase mediated resistance in urinary tract isolates of family Enterobacteriaceae. Indian J Med Res 2002;116:145-9.

Abhilash KP, Veeraraghavan B, Abraham OC. Epidemiology and outcome of bacteremia caused by extended spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. In a tertiary care teaching hospital in south India. J Assoc Physicians India 2010;58 Suppl:13-7.

Wattal C, Goel N, Oberoi JK, Raveendran RS, Datta S, Prasad KJ. Surveillance of multidrug resistant organisms in a tertiary care hospital in Delhi, India. J Assoc Physicians India 2010;58 Suppl:32-6.

Ananthakrishnan AN, Kanungo R, Kumar A, Badrinath S. Detection of extended spectrum beta-lactamase producers among surgical wound infections and burn patients in JIPMER. Indian J Med Microbiol 2000;18:160-5.

Shaikh S, Fatima J, Shakil S, Rizvi MS, Kamal MA. Risk factors for acquisition of extended spectrum beta lactamases producing Escherichia coli and Klebsiella pneumonia in North-Indian hospitals. Saudi J Biol Sci 2015;22:37-41.

Shrestha S, Amatya R, Dutta R. Prevalence of extended spectrum beta lactamase (ESBL) production in gram negative isolates from pyogenic infection in tertiary care hospital of Eastern Nepal. Nepal Med Coll J 2011;13:186-9.

Jain S, Geeta W, Rubina M. Prevalence and antimicrobial susceptibility pattern of ESBL producing gram negative bacilli in 200 cases of urinary tract infections. Int J Pharm Pharm Sci 2014;6:210-1.

Babypadmini S, Appalaraju B. Extended spectrum beta-lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae-prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol 2004;22:172-4.